The stock of Trillium Therapeutics Inc. (NASDAQ:TRIL) hit a new 52-week high and has $44.09 target or 164.00% above today’s $16.70 share price. The 9 months bullish chart indicates low risk for the $127.77 million company. The 1-year high was reported on Oct, 7 by Barchart.com. If the $44.09 price target is reached, the company will be worth $209.54M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 134,093 shares traded hands or 45.28% up from the average. Trillium Therapeutics Inc. (NASDAQ:TRIL) has risen 118.88% since March 4, 2016 and is uptrending. It has outperformed by 110.84% the S&P500.
Analysts await Trillium Therapeutics Inc. (NASDAQ:TRIL) to report earnings on November, 8. They expect $-0.83 EPS, down 418.75% or $0.67 from last year’s $-0.16 per share. After $-0.75 actual EPS reported by Trillium Therapeutics Inc. for the previous quarter, Wall Street now forecasts 10.67% negative EPS growth.
According to Zacks Investment Research, “Trillium Therapeutics Inc. is an immuno-oncology company. It engages in developing therapies for the treatment of cancer. The Company has two premier preclinical programs, SIRP?Fc and a CD200 monoclonal antibody, which target two key immunoregulatory spathway that tumor cells exploit to evade the host immune system. Trillium Therapeutics Inc. is based in Canada.”
More important recent Trillium Therapeutics Inc. (NASDAQ:TRIL) news were published by: Marketwatch.com which released: “Trillium Therapeutics Inc.” on August 24, 2009, also Etfdailynews.com published article titled: “Trillium Therapeutics Inc. (TRIL): Finding The Next Blockbuster Biotech Stock”, Quotes.Wsj.com published: “News Trillium Therapeutics Inc.TRIL” on December 20, 2014. More interesting news about Trillium Therapeutics Inc. (NASDAQ:TRIL) was released by: Seekingalpha.com and their article: “Trillium Therapeutics Is An Overvalued Biotech Stock” with publication date: April 14, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.